Catalent (NYSE:CTLT) Shares Gap Up to $32.14

Shares of Catalent, Inc. (NYSE:CTLT – Get Rating) gapped up before the market opened on Friday . The stock had previously closed at $32.14, but opened at $35.07. Catalent shares last traded at $37.08, with a volume of 5,292,248 shares changing hands.

Analyst Ratings Changes

CTLT has been the subject of several analyst reports. William Blair downgraded Catalent from an “outperform” rating to a “market perform” rating in a research report on Friday, April 14th. Barclays decreased their target price on Catalent from $70.00 to $40.00 in a research report on Monday, April 17th. Royal Bank of Canada decreased their target price on Catalent from $58.00 to $41.00 in a research report on Monday, May 8th. StockNews.com assumed coverage on Catalent in a report on Thursday. They issued a “sell” rating for the company. Finally, Deutsche Bank Aktiengesellschaft downgraded Catalent from a “buy” rating to a “hold” rating and reduced their price target for the company from $55.00 to $29.00 in a report on Monday, May 15th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $74.80.

Catalent Price Performance

The company has a 50 day simple moving average of $53.08 and a 200-day simple moving average of $53.03. The stock has a market cap of $6.69 billion, a price-to-earnings ratio of 16.45, a PEG ratio of 3.97 and a beta of 1.17. The company has a quick ratio of 1.38, a current ratio of 1.91 and a debt-to-equity ratio of 0.86.

Insider Transactions at Catalent

In other news, insider Manja Boerman sold 1,446 shares of the stock in a transaction that occurred on Monday, May 1st. The stock was sold at an average price of $49.86, for a total transaction of $72,097.56. Following the sale, the insider now directly owns 14,414 shares in the company, valued at approximately $718,682.04. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, SVP Mario Gargiulo sold 678 shares of the stock in a transaction that occurred on Monday, May 1st. The stock was sold at an average price of $49.86, for a total value of $33,805.08. Following the completion of the transaction, the senior vice president now directly owns 5,676 shares of the company’s stock, valued at approximately $283,005.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Manja Boerman sold 1,446 shares of the stock in a transaction that occurred on Monday, May 1st. The stock was sold at an average price of $49.86, for a total value of $72,097.56. Following the completion of the transaction, the insider now directly owns 14,414 shares of the company’s stock, valued at $718,682.04. The disclosure for this sale can be found here. Insiders own 0.58% of the company’s stock.

Hedge Funds Weigh In On Catalent

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CTLT. Chevy Chase Trust Holdings LLC boosted its stake in Catalent by 0.7% during the 1st quarter. Chevy Chase Trust Holdings LLC now owns 104,654 shares of the company’s stock valued at $6,877,000 after purchasing an additional 713 shares in the last quarter. KB Financial Partners LLC bought a new position in Catalent during the 1st quarter valued at $30,000. Mercer Global Advisors Inc. ADV boosted its stake in Catalent by 18.7% during the 1st quarter. Mercer Global Advisors Inc. ADV now owns 44,900 shares of the company’s stock valued at $2,950,000 after purchasing an additional 7,081 shares in the last quarter. Hudson Bay Capital Management LP bought a new position in Catalent during the 1st quarter valued at $13,757,000. Finally, Snyder Capital Management L P boosted its stake in Catalent by 0.7% during the 1st quarter. Snyder Capital Management L P now owns 1,169,232 shares of the company’s stock valued at $76,830,000 after purchasing an additional 7,940 shares in the last quarter. 99.38% of the stock is owned by institutional investors.

About Catalent

(Get Rating)

Catalent, Inc is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services.